All Updates

All Updates

icon
Filter
Partnerships
Fujitsu partners with Paradigm to enhance clinical trials and tackle drug loss in Japan
Clinical Trial Technology
Aug 26, 2024
This week:
Partnerships
Apple discloses use of AWS GenAI chips at re:Invent 2024 conference
Generative AI Infrastructure
Today
Product updates
AWS launches Automated Reasoning checks to combat AI hallucinations
Generative AI Infrastructure
Today
Product updates
Roonyx releases enhanced BNPL platform to facilitate secure transactions
Buy Now, Pay Later
Yesterday
Product updates
AWS announces next generation of SageMaker platform at re:Invent 2024
Generative AI Infrastructure
Yesterday
Product updates
Equal1 launches quantum controller chip for cryogenic computing
Quantum Computing
Yesterday
Partnerships
Exotec partners with BlueStar to deploy Skypod warehouse automation system
Logistics Tech
Yesterday
Partnerships
Amaero enters long-term supply agreement with Perryman
Additive Manufacturing
Yesterday
Product updates
Raise3D launches six new resins for DF2 DLP solution
Additive Manufacturing
Yesterday
M&A
Anzu Partners acquires voxeljet for EUR 20 million
Additive Manufacturing
Yesterday
Funding
Soda Health raises USD 50 million in oversubscribed Series B funding to scale operations
Health Benefits Platforms
Yesterday
Clinical Trial Technology

Clinical Trial Technology

Aug 26, 2024

Fujitsu partners with Paradigm to enhance clinical trials and tackle drug loss in Japan

Partnerships

  • Fujitsu, a global technology company, has partnered with Paradigm Health, a US-based clinical trial platform provider, to improve clinical trials and address drug loss in Japan.

  • The partnership aims to streamline medical institution data collection and processing, accelerate clinical trial planning, and attract global trials to Japan. Fujitsu will leverage its Healthy Living Platform, Kozuchi AI service, and a new Patient-centric Clinical Trials service using a proprietary LLM to automate document creation.

  • This collaboration seeks to modernize clinical trials in Japan, increase patient accrual, decrease drug development timelines and costs, and establish Japan as a key player in the global clinical trials ecosystem. Fujitsu aims to secure JPY 20 billion (USD 138 million) in revenue by fiscal 2030 through these efforts.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.